+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Variability in dapsone test to assess CYP3A4 activity



Variability in dapsone test to assess CYP3A4 activity



Pharmaceutical Research (New York) 13(9 Suppl. ): S406




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034181324

Download citation: RISBibTeXText


Related references

CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics 14(2): 137-149, 2013

Comparative value of Dapsone "spot test" and Dapsone "tile test" in leprosy control programme. Indian Journal of Leprosy 56(4): 847-851, 1984

Cisapride A potential model substrate to assess CYP3A4 activity. Clinical Pharmacology & Therapeutics 71(2): P104, 2002

Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food and Chemical Toxicology 41(2): 201-224, 2002

Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food & Chemical Toxicology 41(2): 201-224, 2003

Variability of urinary dapsone/creatinine concentration ratios in leprosy patients fully compliant with dapsone therapy. Leprosy Review 50(2): 129-134, 1979

Variability in activity of hepatic CYP3A4 in patients infected with HIV. Pharmacotherapy 20(8): 898-907, 2000

Spot test for detection of dapsone in urine: an assessment of its validity and interpretation in monitoring dapsone self-administration. International Journal of Leprosy and Other Mycobacterial Diseases 54(1): 21-24, 1986

Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. Journal of Cystic Fibrosis 13(2): 179-185, 2014

Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. Journal of Clinical Pharmacology 39(7): 664-669, 1999

Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10(5): 373-388, 2000

CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clinical Pharmacology and Therapeutics 71(3): 196-204, 2002

Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clinical Pharmacology and Therapeutics 79(4): 339-349, 2006

Inhibitory Effects of Vegetable Juices on CYP3A4 Activity in Recombinant CYP3A4 and LS180 Cells. Biological and Pharmaceutical Bulletin 39(9): 1482-1487, 2017